Inhibikase Therapeutics exchanges 18M shares with RA Capital for pre-funded warrants

Inhibikase Therapeutics, Inc.

RA Capital exchanged 18,030,000 common shares for pre-funded warrants with $0.001 exercise price.
Warrants are immediately exercisable, no expiration, with 9.99% beneficial ownership blocker (can increase to 19.99%).
Issued under Section 3(a)(9) exemption from registration; no new cash raised.
Exchange reduces outstanding shares but introduces potential dilution upon warrant exercise.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.